vascular endothelial growth factor


Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms, Wikipedia.
Related to vascular endothelial growth factor: Platelet derived growth factor

vascular endothelial growth factor

[¦vas·kyə·lər ‚en·dō¦thē·lē·əl ′grōth ‚fak·tər]
(medicine)
A soluble factor that acts through specific cell-surface receptors on endothelial cells to critically regulate vasculogenesis.
References in periodicals archive ?
Expression of vascular endothelial growth factor receptors in the human endometrium: modulation during the menstrual cycle.
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of humancolon cancer.
Use of anti vascular endothelial growth factor drug and ranibizumab and pegaptanib for ocular vascular pathologies was hindered by the high cost of treatment18 especially in developing countries.
Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon.
The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.
The vascular endothelial growth factor (VEGF) +405 G>C 5'-untranslated region polymorphism and increased risk of endometriosis in South Indian women: a case control study.
Similar trends were seen for vascular endothelial growth factor levels.
Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.
Extensive preclinical and clinical research has attributed the sudden abnormal growth of ocular blood vessels to the over-production of vascular endothelial growth factor (VEGF), a protein that stimulates the growth of the endothelial cells that make new blood vessels (a process called angiogenesis).
In the published studies, GRNOPC1 was found to produce numerous neurotrophic factors, including transforming growth factor [eth]1 (TGF-[eth]1), transforming growth factor [eth]2 (TGF-[eth]2), activin A, midkine, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF).
The first drug, bevacizumab, works by inhibiting vascular endothelial growth factor, a protein that directs blood vessel formation in growing tissues, including tumors.
Therapies that block tumor angiogenesis, specifically those that block vascular endothelial growth factor (VEGF), the key initiator of tumor angiogenesis, recently have been validated in human cancer patients.
Full browser ?